Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs].

Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] - 1 Jan 2015

Bogush T A, Popova A S, Dudko E A, Bogush E A, Tyulyandina A S, Tyulyandin S A, Davydov M I

Abstract excerpt

The review is concerned with the crucial marker of nucleotide excision repair ERCC1 and its contribution to platinum resistance of ovarian cancer. All the variants of the laboratory and clinical ERCC1 assessment in the ovarian cancer tissue (single nucleotide polymorphisms of the ERCC1 gene, levels of mRNA or protein) are considered. Data on the prognostic and predictive value of ERCC1 as a marker of the response...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carboplatin

Share to Cisplatin

Share to Drug Resistance, Neoplasm

Share to Endonucleases

Share to Ovarian Neoplasms

Share to Predictive Value of Tests

Source

Identifiers

PMID: 26415382

Genes

ERCC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs].PMID 26415382Read ↗

Platinum Resistance in Ovarian Cancer: Role of DNA RepairSemantic proximity Read ↗

Genetic variants as ovarian cancer first-line treatment hallmarks: A systematic review and meta-analysis.Semantic proximity Read ↗

Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis.Semantic proximity Read ↗

[Advances in research on the association between single nucleotide polymorphisms of the DNA repair genes and resistance to platinum-based chemotherapy].Semantic proximity Read ↗

[Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].Semantic proximity Read ↗

ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.Semantic proximity Read ↗

Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.Semantic proximity Read ↗

Role of common ERCC1 polymorphisms in cisplatin-resistant epithelial ovarian cancer patients: A study in Chinese cohort.Semantic proximity Read ↗

Genetic markers for prediction of treatment outcomes in ovarian cancer.Semantic proximity Read ↗

Excision repair cross complementing-group 1: Gene expression and platinum resistance (Review) parameters in human breast cancerSemantic proximity Read ↗

‘Genetic profiling’ and ovarian cancer therapy (Review)Semantic proximity Read ↗

Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.